Gilead Sciences struck a deal to acquire a preclinical TREX1-targeted oncology program from Sprint Bioscience, committing an initial payment with up to ~$400 million in development and commercial milestones. The asset targets the DNA exonuclease TREX1, a regulator of tumor immune signaling, and represents a strategic bolt-on to Gilead’s expanding oncology portfolio. The transaction underscores big-pharma appetite for small, mechanism-focused preclinical programs that can be accelerated with internal development resources. Terms were described as upfront plus substantial biobucks contingent on progress, highlighting the growing market for early-stage oncology intellectual property.